Logo
WikiMD is the world's largest medical encyclopedia with
13,859 pages, 4,141,228 edits & 40,048,959 views.
Abexinostat
Jump to navigation
Jump to search
^Abexinostat (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
Abexinostat (INN,[1] formerly PCI-24781) is an experimental drug candidate for cancer treatment.[2] It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma.[3] Pre-clinical study suggests the potential for treatment of different types of cancer as well.[4][5][6][7]
Abexinostat exerts its effect as a pan-histone deacetylase inhibitor[8][9] and inhibits RAD51, which is involved in repairing DNA double strand breaks.[10]
References
- ↑ WHO Drug Information, Vol. 25, No. 2, 2011
- ↑ Abexinostat, NCI Cancer Dictionary
- ↑ Abexinostat HCl (PCI-24781), PanHDAC-inhibitor Archived 2013-10-27 at the Wayback Machine, Pharmacyclics
- ↑
- ↑
- ↑
- ↑
- ↑
- ↑
- ↑
Latest research - Abexinostat
Resources for Abexinostat | |
| Uptodate | |
| Medline | |
| About | |
Social media links on Abexinostat
  | |
Abexinostat is part of WikiMD's free ^articles!
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available |
